CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,367 enrolled
Drug / intervention
COPAN 552c.80 FLOQSwabdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05453006
NCT05453006N/ACompleted
CompareCT.gov

Reducing Cervical Cancer Screening Disparities in Somali Immigrant Women Through a Primary Care-based HPV Self-sampling Intervention

University of Minnesota·interventional·Posted Jul 12, 2022·Updated Jul 10, 2025

In Brief

A clinical study evaluating COPAN 552c.80 FLOQSwab for Cervical Cancer and 3 related conditions. Completed, enrolled 3,367 participants across 1 site.

Detailed Summary

This study plans to assess the effect of implementing HPV self-sampling in primary care on uptake of cervical cancer screening in 30-65 year old Somali women who are due for cervical cancer screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer, Papillomavirus Infection, Uterine Diseases, Uterine Cervical Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 12, 2022
Enrollment StartFeb 20, 2023
Primary CompletionMay 19, 2024
Study CompletionMay 19, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.0 years ago

Interventions

COPAN 552c.80 FLOQSwabdevice

The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview non-intervention clinics.